Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD 98.05
+2.15 (2.24%)
Sep 30, 2026, 4:08 PM HKT
Innovent Biologics Market Cap
Innovent Biologics has a market cap or net worth of 170.7 billion as of October 1, 2026. Its market cap has increased by 6.48% in one year.
Market Cap
170.70B
Enterprise Value
150.29B
Revenue
18.13B
Ranking
n/a
PE Ratio
122.05
Stock Price
98.05
ChartMarket Cap Chart
Since October 31, 2018, Innovent Biologics's market cap has increased from 18.54B to 170.70B, an increase of 820.75%. That is a compound annual growth rate of 32.35%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 30, 2026 | 170.70B | 29.06% |
| Dec 31, 2025 | 132.27B | 120.60% |
| Dec 31, 2024 | 59.96B | -13.32% |
| Dec 29, 2023 | 69.17B | 34.57% |
| Dec 30, 2022 | 51.40B | -27.14% |
| Dec 31, 2021 | 70.55B | -38.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Oct 31, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| BeOne Medicines AG | 326.49B |
| WuXi Biologics | 230.01B |
| Sichuan Kelun-Biotech Biopharmaceutical | 116.40B |
| Genscript Biotech | 102.30B |
| Sino Biopharmaceutical | 101.69B |
| Akeso | 100.13B |
| RemeGen | 64.58B |
| Biocytogen Pharmaceuticals (Beijing) | 57.60B |